Innovus Pharma Management Discusses the Company's Revenue Stream and Growth Strategy with TheStockRadio.com

SAN DIEGO, CA / ACCESSWIRE / December 18, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the counter medicine and consumer care products to improve men and women's health and vitality, announced today its recent interview with TheStockRadio.com, Inc. an audio interview company dedicated to raising awareness for small-cap and OTC public companies, is now available at TheStockRadio.com.

Innovus Pharma is based in San Diego and generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for promoting sexual and cognitive health. The Company signed commercial distribution agreements in 28 countries for some of its products and has revenue from multiple international markets in addition to its US sales.

The interview, which took place on December 4, 2014, now appears on TheStockRadio.com website. Lynnette Dillen, Chief Financial Officer and Executive Vice President of Innovus Pharma, details the company's business model, commercial product pipeline, and the increase inrevenues from the sales of its five commercial products.

Explaining the growth strategy of the Company towards profitability, Lynnette says: "We have a three-pronged growth strategy for revenue: The first is generating revenues from our US sales channels and our robust online platform, the second is through our international distribution through our signed commercial partners in 28 countries, and the third through acquiring or in-licensing new products that we can readily commercialize through all of the channels.The advantage of the Company is the type of products it has and the therapeutic areas we are in. All of our products have strong clinical trials supporting their efficacy and safety. Our goal is to have our products in at least 40 countries by the end of 2015 and push our way towards profitability", continued Ms. Dillen. She added, "2015 for us is really about three things - new products, higher sales and profitability."

Full audio can be found at http://thestockradio.com/innv-innovus-pharmaceuticals-inc-evp-cfo-lynnette-dillen/.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The company generates revenues from its lead products Zestra(R) for female arousal and EjectDelay(R) for premature ejaculation and has a total of five marketed products in this space, including Sensum+(R) (for sales outside the U.S. only), Zestra Glide(R) and Vesele(R) for promoting sexual and cognitive health.

For more information, visit www.innovuspharma.com, www.zestra.com; www.myvesele.com; www.sensumplus.com.

Innovus Pharma's Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the company, including, but not limited to, receiving patent protection for any of its products, receiving approval or to be compliant with the requirements of any relevant regulatory authority relating to such products such as Zestra(R), to successfully commercialize such products and to achieve its other development, commercialization, financial and staffing objectives including realizing any or all of the approximate $330 million in milestone payments from our corporate partners from the sale of our products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact:

Chesapeake Group
Kevin Holmes
info@chesapeakegp.com
410-825-3930



SOURCE: Innovus Pharmaceuticals, Inc.